| Date | Title | Description |
| 17.04.2013 | BEATBio Closes $2.5M Seed Round |
SEATTLE, WA, Biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure, today announced the closing of a $2.5 million seed stage investment.
>> Click her... |
| 17.04.2013 | Gene therapy to restore muscle power to the heart nets UW spinoff $2.5 million | That technology was spun into a company in 2008 with grants from the National Institutes of Health. Seattle-based BEAT is now led by Michael Kranda, a former chief operating officer of Immunex and CEO of Vaccinogen.
Celladon Corp. and Belgi... |
| 16.04.2013 | BEATBio Closes $2.5M Seed Funding Round | BEATBio, a Seattle, Wash.-based biotechnology company focused on the development of a novel gene therapy for heart failure, closed a $2.5m seed funding.
Backers included CET Capital Partners, with participation from the W Fund.
The company ... |
| - | Gene therapy to restore muscle power to the heart nets UW spinoff $2.5 million | Damaged or weakened heart muscle that can’t pump enough blood to the rest of the body causes a host of problems that fall under the classification of heart failure. Researchers at the University of Washington have discovered a gene-based me... |